These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10454204)

  • 1. Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies.
    Noble ME; Endicott JA
    Pharmacol Ther; 1999; 82(2-3):269-78. PubMed ID: 10454204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design of cyclin-dependent kinase inhibitors.
    Davies TG; Pratt DJ; Endicott JA; Johnson LN; Noble ME
    Pharmacol Ther; 2002; 93(2-3):125-33. PubMed ID: 12191605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of the binding modes of ATP-competitive CDK2 inhibitors as revealed by X-ray structures of protein-inhibitor complexes.
    Vulpetti A; Pevarello P
    Curr Med Chem Anticancer Agents; 2005 Sep; 5(5):561-73. PubMed ID: 16178778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors.
    Jeffrey PD; Tong L; Pavletich NP
    Genes Dev; 2000 Dec; 14(24):3115-25. PubMed ID: 11124804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structure of a viral cyclin, a positive regulator of cyclin-dependent kinase 6.
    Schulze-Gahmen U; Jung JU; Kim SH
    Structure; 1999 Mar; 7(3):245-54. PubMed ID: 10368294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a potential allosteric ligand binding site in CDK2.
    Betzi S; Alam R; Martin M; Lubbers DJ; Han H; Jakkaraj SR; Georg GI; Schönbrunn E
    ACS Chem Biol; 2011 May; 6(5):492-501. PubMed ID: 21291269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
    Kalra S; Joshi G; Munshi A; Kumar R
    Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design.
    Kontopidis G; McInnes C; Pandalaneni SR; McNae I; Gibson D; Mezna M; Thomas M; Wood G; Wang S; Walkinshaw MD; Fischer PM
    Chem Biol; 2006 Feb; 13(2):201-11. PubMed ID: 16492568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-directed mutant p21 proteins defective in both inhibition of E2F-regulated transcription and disruption of E2F-p130-cyclin-cdk2 complexes.
    Robles SJ; Shiyanov P; Aristodemo GT; Raychaudhuri P; Adami GR
    DNA Cell Biol; 1998 Jan; 17(1):9-18. PubMed ID: 9468218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.
    Fischer PM; Lane DP
    Curr Med Chem; 2000 Dec; 7(12):1213-45. PubMed ID: 11032968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selectivity and potency of cyclin-dependent kinase inhibitors.
    Sridhar J; Akula N; Pattabiraman N
    AAPS J; 2006 Mar; 8(1):E204-21. PubMed ID: 16584130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of CDK2 active-site hydration: a method to design new inhibitors.
    Kríz Z; Otyepka M; Bártová I; Koca J
    Proteins; 2004 May; 55(2):258-74. PubMed ID: 15048820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
    De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
    Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
    Nandha Premnath P; Craig S; McInnes C
    J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes.
    Naumann T; Matter H
    J Med Chem; 2002 Jun; 45(12):2366-78. PubMed ID: 12036347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine.
    Schulze-Gahmen U; Brandsen J; Jones HD; Morgan DO; Meijer L; Vesely J; Kim SH
    Proteins; 1995 Aug; 22(4):378-91. PubMed ID: 7479711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin E-CDK2 is a regulator of p27Kip1.
    Sheaff RJ; Groudine M; Gordon M; Roberts JM; Clurman BE
    Genes Dev; 1997 Jun; 11(11):1464-78. PubMed ID: 9192873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell cycle molecular targets in novel anticancer drug discovery.
    Buolamwini JK
    Curr Pharm Des; 2000 Mar; 6(4):379-92. PubMed ID: 10788588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.